• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Holdings
Company Encyclopedia
View More
name
China Merchants Ruizhi Selected Flexible Configuration Hybrid Fund(LOF)
161728.SZ
Shareholder
Ownership%OwnedShare ChgReport Date
No Data
News
View More

The stock market "long-term buyers" are taking shape

The channel for Chinese insurance funds to increase their allocation to A-shares is being systematically opened up. With the continuous growth of life insurance premiums, it is gradually becoming a stable "supply line" of long-term capital for the A-share market

Wallstreetcn·Yesterday at 09:19
SH
601336
+1.37%
HK
01336
-0.49%
SH
601601
+2.05%
Wallstreetcn·Yesterday at 09:19
SH
601336
+1.37%
HK
01336
-0.49%
SH
601601
+2.05%

Yuexiu Property Reports 49% Drop in November Contracted Sales

Yuexiu Property Co. Ltd. reported a 49% year-on-year drop in November 2025 contracted sales, totaling RMB 5,115 million. The gross floor area decreased by 45% to 184,100 square meters. From January to November 2025, total contracted sales were RMB 97,218 million, down 3.8% year-on-year, with a GFA decrease of 27% to 2,504,900 square meters. The sales value reached 80.7% of the 2025 target of RMB 120.5 billion. No new land was acquired in November.

Reuters·12/12/2025 20:05
HK
00123
+0.72%
Reuters·12/12/2025 20:05
HK
00123
+0.72%
© 2025 Longbridge|Disclaimer

Event Tracking

Dec13
2025 National Medical Insurance Drug Directory Update, Hengrui and Eli Lilly are Major Winners
03:47
Dec12
China Resources Land Announces Sales Performance and Regular Income for January to November 2025
13:20
Yuexiu Properties Reports 49% Drop in Sales in November 2025
12:05
Hengrui Medicine's Subsidiary Receives Clinical Trial Approval Notice for RSS0343 Tablets from NMPA
11:57
HRS9531 Injection Approved for Clinical Trials by Huahai Medicine's Subsidiary
11:53
Morgan Stanley Reduces Its Holding in Hengrui Medicine
09:22